Abstract
Clinical studies are currently underway to assess the biodistribution and therapeutic potential of the genetically engineered human antibody hCTM01 directed against polymorphic epithelial mucin (PEM) in patients with ovarian carcinoma. The present study was undertaken to assess the effect of circulating PEM antigen on the biodistribution of the anti-PEM antibody in mice bearing MUC-1 transfected adenocarcinoma cell lines. Tumour xenografts were established from three cell lines: 413-BCR, which expressed antigen on the cell surface and also shed antigen into the circulation, E3P23, which expressed the antigen but dit not shed into the ciruclation, and a negative control (410.4 MUCI). Groups of five mice were injected with 1.0 mg/kg antibody, imaged after 72 h and then sacrificed, followed by assay of tissue uptake. The results showed a clear difference in the tumour and liver uptake, with the non-secreting cell line showing almost twice the tumour uptake and approximately 20% of the liver uptake of the secreting cell line.
This is a preview of subscription content, log in via an institution to check access.
References
Perkins AC, Pimm MV.Immunoscintigraphy: practical aspects and clinical practice. New York: Wiley Liss: 1991.
Pimm MV. Circulating antigen: bad or good for immunoscintigraphy?Nucl Med Biol 1995; 22: 137–145
Davies Q, Symonds IM, Perkins AC, Kerslake RW, Wastie ML, Worthington BS, Symonds EM. Magnetic resonance imaging, OC125 immunoscintigraphy and serum CA125 levels in patients with suspected primary or recurrent ovarian carcinoma.J Obstet Gynaecol 1996; 16: 108–116.
Roos JC, Perkins AC, van Hof A, Davies Q, Molthoff C, den Hollander W, Wilhelm A, Verheijen R, Frier M, Vermorken J, van Lingen A, Baker T, Symonds EM, Kenemans P. In-111-hCTM01 monoclonal antibody (Mab) in patients with ovarian cancer: immunoscintigraphy and biodistribution.Eur J Nucl Med 1994; 21: 769.
Hagen PL, Halpern SE, Chen A, Krisnan L, Frincke J, Bartholemew RM, David GS, Carlo D. In vivo kinetics of radiolabelled anti-CEA monoclonal antibodies in animal models.J Nucl Med 1985; 26: 1418–1423.
Douillard YC, Chatal J-F, Curtet C, Kremer M, Peuvrel P, Koprowski H. Pharmacokinetic study of radiolabelled anti-colorectal carcinoma monoclonal antibodies in tumour bearing nude mice.Eur J Nucl Med 1985; 11: 107–113
Sands H, Jones PL. Methods for the study of the metabolism of radiolabelled monoclonal antibodies by liver and tumour.J Nucl Med 1987; 28: 390–398.
Watanabe Y, Endo K, Koizumi M, Kawamura Y, Saga T, Sakahara H, Kuroki M, Matsuoka Y, Konishi J. Effect of tumour mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice.Cancer Res 1989; 49: 2884–2889.
Beatty BG, Beatty JD, Williams LE, Paxton RJ, Shively JE, Oconnor-Tressel M. Effect of specific antibody pretreatment on liver uptake of 111-indium-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts.Cancer Res 1989; 49: 1587–1594.
Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabelled anti-B1 monoclonal antibody.Cancer Res 1992; 52: 637–642.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davies, Q., Perkins, A.C., Frier, M. et al. The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur J Nucl Med 24, 206–209 (1997). https://doi.org/10.1007/BF02439555
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02439555